For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $1.6 in the prior trading day, Macrogenics Inc (NASDAQ: MGNX) closed at $1.66, up 4.08%. In other words, the price has increased by $4.08 from its previous closing price. On the day, 0.85 million shares were traded. MGNX stock price reached its highest trading level at $1.68 during the session, while it also had its lowest trading level at $1.56.
Ratios:
Our goal is to gain a better understanding of MGNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.02 and its Current Ratio is at 5.25. In the meantime, Its Debt-to-Equity ratio is 2.31 whereas as Long-Term Debt/Eq ratio is at 2.20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when HEIDEN WILLIAM K bought 50,500 shares for $1.52 per share. The transaction valued at 76,760 led to the insider holds 61,500 shares of the business.
HEIDEN WILLIAM K bought 49,500 shares of MGNX for $73,755 on Aug 20 ’25. The Director now owns 111,000 shares after completing the transaction at $1.49 per share. On Feb 15 ’25, another insider, Smith Beth Ann, who serves as the VP, Controller & Treasurer of the company, sold 423 shares for $2.56 each. As a result, the insider received 1,083 and left with 9,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 104921464 and an Enterprise Value of 35942468. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.63 while its Price-to-Book (P/B) ratio in mrq is 2.25. Its current Enterprise Value per Revenue stands at 0.217 whereas that against EBITDA is -0.51.
Stock Price History:
The Beta on a monthly basis for MGNX is 1.56, which has changed by -0.5513513 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, MGNX has reached a high of $5.10, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is -3.96%, while the 200-Day Moving Average is calculated to be -8.00%.
Shares Statistics:
The stock has traded on average 766.76K shares per day over the past 3-months and 1143020 shares per day over the last 10 days, according to various share statistics. A total of 63.21M shares are outstanding, with a floating share count of 58.06M. Insiders hold about 8.14% of the company’s shares, while institutions hold 71.98% stake in the company. Shares short for MGNX as of 1760486400 were 3557143 with a Short Ratio of 4.64, compared to 1757894400 on 3730266. Therefore, it implies a Short% of Shares Outstanding of 3557143 and a Short% of Float of 6.92.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$1.71 and -$1.71 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$2.78, with 1.0 analysts recommending between -$2.78 and -$2.78.
Revenue Estimates
5 analysts predict $28.72M in revenue for . The current quarter. It ranges from a high estimate of $48.18M to a low estimate of $15M. As of . The current estimate, Macrogenics Inc’s year-ago sales were $110.71MFor the next quarter, 5 analysts are estimating revenue of $33.89M. There is a high estimate of $61.7M for the next quarter, whereas the lowest estimate is $9.6M.
A total of 4 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $128.41M, while the lowest revenue estimate was $60M, resulting in an average revenue estimate of $88.53M. In the same quarter a year ago, actual revenue was $149.96MBased on 5 analysts’ estimates, the company’s revenue will be $102.02M in the next fiscal year. The high estimate is $214.39M and the low estimate is $11M.
